Compare Stocks: ANVS, ALXO, IVVD, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.04 +3.3%	$1.92	$0.80 ▼ $2.66	$281.39M	0.42	1.05 million shs	488,244 shs
ANVS Annovis Bio	$1.76 +0.9%	$1.80	$1.54 ▼ $5.50	$60.81M	1.25	812,074 shs	226,549 shs
ARCT Arcturus Therapeutics	$8.20 +0.7%	$6.79	$5.50 ▼ $24.17	$232.62M	2.39	482,679 shs	254,009 shs
IVVD Invivyd	$0.86 +15.6%	$0.77	$0.48 ▼ $3.07	$251.30M	0.71	3.53 million shs	5.54 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+0.51%	-4.37%	-6.19%	+0.51%	+205.76%
ANVS Annovis Bio	-4.61%	-5.38%	+1.21%	-9.04%	-35.53%
ARCT Arcturus Therapeutics	-1.09%	+15.46%	+34.55%	+21.67%	-58.21%
IVVD Invivyd	+2.85%	+10.01%	-0.27%	-28.80%	+4.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.04 +3.3%	$1.92	$0.80 ▼ $2.66	$281.39M	0.42	1.05 million shs	488,244 shs
ANVS Annovis Bio	$1.76 +0.9%	$1.80	$1.54 ▼ $5.50	$60.81M	1.25	812,074 shs	226,549 shs
ARCT Arcturus Therapeutics	$8.20 +0.7%	$6.79	$5.50 ▼ $24.17	$232.62M	2.39	482,679 shs	254,009 shs
IVVD Invivyd	$0.86 +15.6%	$0.77	$0.48 ▼ $3.07	$251.30M	0.71	3.53 million shs	5.54 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+0.51%	-4.37%	-6.19%	+0.51%	+205.76%
ANVS Annovis Bio	-4.61%	-5.38%	+1.21%	-9.04%	-35.53%
ARCT Arcturus Therapeutics	-1.09%	+15.46%	+34.55%	+21.67%	-58.21%
IVVD Invivyd	+2.85%	+10.01%	-0.27%	-28.80%	+4.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	126.04% Upside
ANVS Annovis Bio	2.60	Moderate Buy	$11.67	564.77% Upside
ARCT Arcturus Therapeutics	2.64	Moderate Buy	$24.25	195.73% Upside
IVVD Invivyd	2.33	Hold	$8.00	834.58% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, IVVD, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/6/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
ARCT Arcturus Therapeutics	$82.03M	2.84	N/A	N/A	$7.53 per share	1.09
IVVD Invivyd	$53.43M	4.72	N/A	N/A	$1.04 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-448.41%	-272.53%	N/A
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	N/A
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)

Latest ANVS, ALXO, IVVD, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
ANVS Annovis Bio	N/A	1.27	1.27
ARCT Arcturus Therapeutics	N/A	5.88	5.88
IVVD Invivyd	N/A	5.87	5.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
ARCT Arcturus Therapeutics	94.54%
IVVD Invivyd	70.36%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
ANVS Annovis Bio	20.80%
ARCT Arcturus Therapeutics	17.80%
IVVD Invivyd	12.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
ANVS Annovis Bio	3	34.65 million	27.44 million	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
IVVD Invivyd	100	294.61 million	258.52 million	Optionable

ANVS, ALXO, IVVD, and ARCT Headlines

Recent News About These Companies

Invivyd (NASDAQ:IVVD) Announces Earnings Results, Beats Expectations By $0.01 EPS

August 13, 2026 | marketbeat.com

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026 | globenewswire.com

Invivyd, Inc. (NASDAQ:IVVD) Given Average Recommendation of "Hold" by Analysts

August 8, 2026 | americanbankingnews.com

Invivyd (IVVD) to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2026 | globenewswire.com

Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Rating of "Hold" from Analysts

August 3, 2026 | marketbeat.com

Invivyd (NASDAQ:IVVD) Stock Price Up 7.1% - Here's What Happened

July 31, 2026 | marketbeat.com

Invivyd Receives Nasdaq Notice for Bid Price Deficiency

July 24, 2026 | tipranks.com

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 6, 2026 | markets.businessinsider.com

IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval

July 6, 2026 | finance.yahoo.com

Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down

July 6, 2026 | quiverquant.comQ

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 6, 2026 | globenewswire.com

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

June 29, 2026 | globenewswire.com

Invivyd Posts Strong Q1 Results, Advances VYD2311 Programs

June 25, 2026 | theglobeandmail.com

Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311

June 19, 2026 | finance.yahoo.com

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

June 16, 2026 | globenewswire.com

Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode

June 12, 2026 | insidermonkey.com

Invivyd doses first participants in Phase 3 COVID-19 trial

June 9, 2026 | proactiveinvestors.com

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to ...

June 9, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, IVVD, and ARCT Company Descriptions

ALX Oncology NASDAQ:ALXO

$2.04 +0.07 (+3.30%)

As of 01:45 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$1.76 +0.02 (+0.86%)

As of 01:45 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Arcturus Therapeutics NASDAQ:ARCT

$8.20 +0.06 (+0.74%)

As of 01:46 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Invivyd NASDAQ:IVVD

$0.86 +0.12 (+15.60%)

As of 01:45 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, IVVD, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, IVVD, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, IVVD, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, IVVD, and ARCT Company Descriptions

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Arcturus Therapeutics NASDAQ:ARCT

Invivyd NASDAQ:IVVD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, IVVD, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, IVVD, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, IVVD, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, IVVD, and ARCT Company Descriptions

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Arcturus Therapeutics NASDAQ:ARCT

Invivyd NASDAQ:IVVD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools